Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-97 |
Sentence |
denotes |
Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. |
T1 |
0-97 |
Sentence |
denotes |
Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. |
T2 |
98-109 |
Sentence |
denotes |
BACKGROUND: |
T2 |
98-109 |
Sentence |
denotes |
BACKGROUND: |
T3 |
110-227 |
Sentence |
denotes |
A patient's infectivity is determined by the presence of the virus in different body fluids, secretions, and excreta. |
T3 |
110-227 |
Sentence |
denotes |
A patient's infectivity is determined by the presence of the virus in different body fluids, secretions, and excreta. |
T4 |
228-370 |
Sentence |
denotes |
The persistence and clearance of viral RNA from different specimens of patients with 2019 novel coronavirus disease (COVID-19) remain unclear. |
T4 |
228-370 |
Sentence |
denotes |
The persistence and clearance of viral RNA from different specimens of patients with 2019 novel coronavirus disease (COVID-19) remain unclear. |
T5 |
371-609 |
Sentence |
denotes |
This study analyzed the clearance time and factors influencing 2019 novel coronavirus (2019-nCoV) RNA in different samples from patients with COVID-19, providing further evidence to improve the management of patients during convalescence. |
T5 |
371-609 |
Sentence |
denotes |
This study analyzed the clearance time and factors influencing 2019 novel coronavirus (2019-nCoV) RNA in different samples from patients with COVID-19, providing further evidence to improve the management of patients during convalescence. |
T6 |
610-618 |
Sentence |
denotes |
METHODS: |
T6 |
610-618 |
Sentence |
denotes |
METHODS: |
T7 |
619-799 |
Sentence |
denotes |
The clinical data and laboratory test results of convalescent patients with COVID-19 who were admitted to from January 20, 2020 to February 10, 2020 were collected retrospectively. |
T7 |
619-799 |
Sentence |
denotes |
The clinical data and laboratory test results of convalescent patients with COVID-19 who were admitted to from January 20, 2020 to February 10, 2020 were collected retrospectively. |
T8 |
800-963 |
Sentence |
denotes |
The reverse transcription polymerase chain reaction (RT-PCR) results for patients' oropharyngeal swab, stool, urine, and serum samples were collected and analyzed. |
T8 |
800-963 |
Sentence |
denotes |
The reverse transcription polymerase chain reaction (RT-PCR) results for patients' oropharyngeal swab, stool, urine, and serum samples were collected and analyzed. |
T9 |
964-1174 |
Sentence |
denotes |
Convalescent patients refer to recovered non-febrile patients without respiratory symptoms who had two successive (minimum 24 h sampling interval) negative RT-PCR results for viral RNA from oropharyngeal swabs. |
T9 |
964-1174 |
Sentence |
denotes |
Convalescent patients refer to recovered non-febrile patients without respiratory symptoms who had two successive (minimum 24 h sampling interval) negative RT-PCR results for viral RNA from oropharyngeal swabs. |
T10 |
1175-1341 |
Sentence |
denotes |
The effects of cluster of differentiation 4 (CD4)+ T lymphocytes, inflammatory indicators, and glucocorticoid treatment on viral nucleic acid clearance were analyzed. |
T10 |
1175-1341 |
Sentence |
denotes |
The effects of cluster of differentiation 4 (CD4)+ T lymphocytes, inflammatory indicators, and glucocorticoid treatment on viral nucleic acid clearance were analyzed. |
T11 |
1342-1350 |
Sentence |
denotes |
RESULTS: |
T11 |
1342-1350 |
Sentence |
denotes |
RESULTS: |
T12 |
1351-1448 |
Sentence |
denotes |
In the 292 confirmed cases, 66 patients recovered after treatment and were included in our study. |
T12 |
1351-1448 |
Sentence |
denotes |
In the 292 confirmed cases, 66 patients recovered after treatment and were included in our study. |
T13 |
1449-1553 |
Sentence |
denotes |
In total, 28 (42.4%) women and 38 men (57.6%) with a median age of 44.0 (34.0-62.0) years were analyzed. |
T13 |
1449-1553 |
Sentence |
denotes |
In total, 28 (42.4%) women and 38 men (57.6%) with a median age of 44.0 (34.0-62.0) years were analyzed. |
T14 |
1554-1660 |
Sentence |
denotes |
After in-hospital treatment, patients' inflammatory indicators decreased with improved clinical condition. |
T14 |
1554-1660 |
Sentence |
denotes |
After in-hospital treatment, patients' inflammatory indicators decreased with improved clinical condition. |
T15 |
1661-1810 |
Sentence |
denotes |
The median time from the onset of symptoms to first negative RT-PCR results for oropharyngeal swabs in convalescent patients was 9.5 (6.0-11.0) days. |
T15 |
1661-1810 |
Sentence |
denotes |
The median time from the onset of symptoms to first negative RT-PCR results for oropharyngeal swabs in convalescent patients was 9.5 (6.0-11.0) days. |
T16 |
1811-2066 |
Sentence |
denotes |
By February 10, 2020, 11 convalescent patients (16.7%) still tested positive for viral RNA from stool specimens and the other 55 patients' stool specimens were negative for 2019-nCoV following a median duration of 11.0 (9.0-16.0) days after symptom onset. |
T16 |
1811-2066 |
Sentence |
denotes |
By February 10, 2020, 11 convalescent patients (16.7%) still tested positive for viral RNA from stool specimens and the other 55 patients' stool specimens were negative for 2019-nCoV following a median duration of 11.0 (9.0-16.0) days after symptom onset. |
T17 |
2067-2232 |
Sentence |
denotes |
Among these 55 patients, 43 had a longer duration until stool specimens were negative for viral RNA than for throat swabs, with a median delay of 2.0 (1.0-4.0) days. |
T17 |
2067-2232 |
Sentence |
denotes |
Among these 55 patients, 43 had a longer duration until stool specimens were negative for viral RNA than for throat swabs, with a median delay of 2.0 (1.0-4.0) days. |
T18 |
2233-2426 |
Sentence |
denotes |
Results for only four (6.9%) urine samples were positive for viral nucleic acid out of 58 cases; viral RNA was still present in three patients' urine specimens after throat swabs were negative. |
T18 |
2233-2426 |
Sentence |
denotes |
Results for only four (6.9%) urine samples were positive for viral nucleic acid out of 58 cases; viral RNA was still present in three patients' urine specimens after throat swabs were negative. |
T19 |
2427-2666 |
Sentence |
denotes |
Using a multiple linear regression model (F = 2.669, P = 0.044, and adjusted R = 0.122), the analysis showed that the CD4+ T lymphocyte count may help predict the duration of viral RNA detection in patients' stools (t = -2.699, P = 0.010). |
T19 |
2427-2666 |
Sentence |
denotes |
Using a multiple linear regression model (F = 2.669, P = 0.044, and adjusted R = 0.122), the analysis showed that the CD4+ T lymphocyte count may help predict the duration of viral RNA detection in patients' stools (t = -2.699, P = 0.010). |
T20 |
2667-3122 |
Sentence |
denotes |
The duration of viral RNA detection from oropharyngeal swabs and fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (15 days vs. 8.0 days, respectively; t = 2.550, P = 0.013) and the duration of viral RNA detection in fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (20 days vs. 11 days, respectively; t = 4.631, P < 0.001). |
T20 |
2667-3122 |
Sentence |
denotes |
The duration of viral RNA detection from oropharyngeal swabs and fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (15 days vs. 8.0 days, respectively; t = 2.550, P = 0.013) and the duration of viral RNA detection in fecal samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (20 days vs. 11 days, respectively; t = 4.631, P < 0.001). |
T21 |
3123-3303 |
Sentence |
denotes |
There was no statistically significant difference in inflammatory indicators between patients with positive fecal viral RNA test results and those with negative results (P > 0.05). |
T21 |
3123-3303 |
Sentence |
denotes |
There was no statistically significant difference in inflammatory indicators between patients with positive fecal viral RNA test results and those with negative results (P > 0.05). |
T22 |
3304-3316 |
Sentence |
denotes |
CONCLUSIONS: |
T22 |
3304-3316 |
Sentence |
denotes |
CONCLUSIONS: |
T23 |
3317-3498 |
Sentence |
denotes |
In brief, as the clearance of viral RNA in patients' stools was delayed compared to that in oropharyngeal swabs, it is important to identify viral RNA in feces during convalescence. |
T23 |
3317-3498 |
Sentence |
denotes |
In brief, as the clearance of viral RNA in patients' stools was delayed compared to that in oropharyngeal swabs, it is important to identify viral RNA in feces during convalescence. |
T24 |
3499-3678 |
Sentence |
denotes |
Because of the delayed clearance of viral RNA in the glucocorticoid treatment group, glucocorticoids are not recommended in the treatment of COVID-19, especially for mild disease. |
T24 |
3499-3678 |
Sentence |
denotes |
Because of the delayed clearance of viral RNA in the glucocorticoid treatment group, glucocorticoids are not recommended in the treatment of COVID-19, especially for mild disease. |
T25 |
3679-3742 |
Sentence |
denotes |
The duration of RNA detection may relate to host cell immunity. |
T25 |
3679-3742 |
Sentence |
denotes |
The duration of RNA detection may relate to host cell immunity. |